287 related articles for article (PubMed ID: 8837987)
1. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.
Himelhoch S; Taylor SF; Goldman RS; Tandon R
Biol Psychiatry; 1996 Feb; 39(3):227-9. PubMed ID: 8837987
[No Abstract] [Full Text] [Related]
2. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta.
Sumiyoshi T; Higuchi Y; Itoh T; Matsui M; Arai H; Suzuki M; Kurachi M; Sumiyoshi C; Kawasaki Y
Psychiatry Res; 2009 Jun; 172(3):180-3. PubMed ID: 19386475
[TBL] [Abstract][Full Text] [Related]
3. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
Semkovska M; Bédard MA; Stip E
Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
[TBL] [Abstract][Full Text] [Related]
4. [Absence of frontal lobe dysfunction and working memory deficits in young schizophrenic patients].
Moreaud O; Peguet I; Naegele B; Vincent T; Chabannes JP; Pellat J
Encephale; 1998; 24(1):52-6. PubMed ID: 9559304
[TBL] [Abstract][Full Text] [Related]
5. Influence of haloperidol on the relationship of frontal lobe function to psychomotor poverty and disorganization syndromes.
Allen DN; Anastasiou A; Goldstein G; Gilbertson M; van Kammen DP
Psychiatry Res; 2000 Feb; 93(1):33-9. PubMed ID: 10699226
[TBL] [Abstract][Full Text] [Related]
6. Refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine.
Burke JG; Dursun SM; Reveley MA
J Psychiatry Neurosci; 1999 Nov; 24(5):456-61. PubMed ID: 10586537
[TBL] [Abstract][Full Text] [Related]
7. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
[TBL] [Abstract][Full Text] [Related]
8. [Effects of neuroleptics on the frontal functions of schizophrenics].
Verdoux H; Magnin E; Bourgeois M
Ann Med Psychol (Paris); 1994 Oct; 152(8):530-4. PubMed ID: 7818228
[No Abstract] [Full Text] [Related]
9. Insight, symptoms and executive functions in schizophrenia.
Simon AE; Berger GE; Giacomini V; Ferrero F; Mohr S
Cogn Neuropsychiatry; 2006 Sep; 11(5):437-51. PubMed ID: 17354080
[TBL] [Abstract][Full Text] [Related]
10. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
[TBL] [Abstract][Full Text] [Related]
11. Movement disorders and psychological tests of frontal lobe function in schizophrenic patients.
Brown KW; White T; Palmer D
Psychol Med; 1992 Feb; 22(1):69-77. PubMed ID: 1349440
[TBL] [Abstract][Full Text] [Related]
12. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia.
Stip E; Fahim C; Mancini-Marïe A; Bentaleb LA; Mensour B; Mendrek A; Beauregard M
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):21-6. PubMed ID: 15610941
[TBL] [Abstract][Full Text] [Related]
13. Attention disorders in schizophrenia.
Suwa H; Matsushima E; Ohta K; Mori K
Psychiatry Clin Neurosci; 2004 Jun; 58(3):249-56. PubMed ID: 15149289
[TBL] [Abstract][Full Text] [Related]
14. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
[TBL] [Abstract][Full Text] [Related]
15. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
[TBL] [Abstract][Full Text] [Related]
16. Perospirone in the treatment of schizophrenia: effect on verbal memory organization.
Araki T; Yamasue H; Sumiyoshi T; Kuwabara H; Suga M; Iwanami A; Kato N; Kasai K
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):204-8. PubMed ID: 16300872
[TBL] [Abstract][Full Text] [Related]
17. Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment.
Chua SE; Deng Y; Chen EY; Law CW; Chiu CP; Cheung C; Wong JC; Lienenkaëmper N; Cheung V; Suckling J; McAlonan GM
Psychol Med; 2009 May; 39(5):793-800. PubMed ID: 18713487
[TBL] [Abstract][Full Text] [Related]
18. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
19. The relationship of the brief psychiatric rating scale to neuropsychological deficits in phenothiazine-treated schizophrenics.
Golden CJ; Carpenter B; Wilkening G; Ruedrich S; Chu CC; Graber B
Psychopharmacol Bull; 1983; 19(3):513-7. PubMed ID: 6138799
[No Abstract] [Full Text] [Related]
20. Simple schizophrenia in an adolescent.
Valentí M; Castro-Fornieles J; Lázaro ML; Sugrañes G; Baeza I
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):589-90. PubMed ID: 19877985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
